Ulrike Rauh

Years Active: 2024-2024
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)

Ulrike Rauh.css-eqlu8i{font-size:small;padding-left:4px;}